Print

University College London, Moorfields Eye Hospital and Targeted Genetics Corporation (TGEN) Initiate Phase I/II Clinical Trial of Gene Therapy for Childhood Blindness  
5/1/2007 10:45:06 AM

LONDON and SEATTLE, WA -- (MARKET WIRE) -- May 01, 2007 -- University College London's (UCL) Institute of Ophthalmology, Moorfields Eye Hospital and Targeted Genetics Corporation (NASDAQ: TGEN) today announced the initiation of a Phase I/II clinical trial to test an innovative approach to treating a form of childhood blindness. The trial, funded by the UK Department of Health is the first of its kind and could have a significant impact on future treatments for eye disease.
//-->